Preclinical Data for a Topical Formulation of Voclosporin as a Potential Best-in-Class Treatment for Chronic Inflammatory Eye Diseases Presented at ARVO



    EDMONTON, July 31 /CNW/ - (ISA:TSX): Isotechnika Inc. today announced
that its partner, Lux Biosciences, presented preclinical data demonstrating
the safety and pharmacokinetics of LX214 as a potential once-daily topical
treatment for chronic inflammatory diseases of the eye. LX214 is a clear,
micellar topical formulation of voclosporin, Isotechnika's next-generation
calcineurin inhibitor, which is being developed by Lux Biosciences as a
potential treatment for such conditions as dry eye syndrome, blepharitis, and
atopic keratoconjunctivitis.
    Lux Biosciences researchers and collaborators presented the data in a
poster session at the ARVO Summer Eye Research Conference, "Ocular Immunity
and Inflammation" being held from July 31 - August 2 at the Portola Plaza
Hotel in Monterey, CA. Highlights of the data included:

    
    -   Concentrations of voclosporin established therapeutic levels in tear
        fluid and most ocular tissues after single or multiple topical
        applications of LX214. Blood levels remained at or near base line,
        and there was minimal distribution of voclosporin to the opposite,
        non-treated eye indicating no systematic exposure to the drug.
    -   Tissue concentrations of voclosporin in the target tissues were
        significantly higher than the tissue concentrations of cyclosporine A
        achieved by twice daily topical application of Restasis(R)
        (cyclosporine 0.05%) suggesting greater efficacy over Restasis(R) and
        the potential for once-a-day dosing.
    -   These results are particularly important given that voclosporin has
        been shown to be four-fold more potent than cyclosporine A.
    -   No evidence of clinical irritation or melanin binding was observed in
        any of the animals treated with LX214.
    

    "These data strongly support the further development of LX214 as a
topical product for serious ocular inflammatory conditions as well as for dry
eye syndrome," said Ulrich Grau, Ph.D., President and Chief Executive Officer
of Lux Biosciences. "We believe that the product has best-in-class potential
based on the preclinical findings."

    About Isotechnika
    -----------------
    Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential will exceed $4 billion annually in sales
for calcineurin inhibitors such as voclosporin by 2010.
    Voclosporin is a next generation calcineurin inhibitor, which recently
completed a Phase 2b North American trial for the prevention of kidney
rejection following transplantation. An extension to the Phase 2b trial and a
combined Phase 3 European/Canadian trial for the treatment of moderate to
severe psoriasis are ongoing. Our partner, Lux Biosciences, is currently
conducting three separate Phase 2/3 pivotal trials investigating voclosporin
(referred to as LUVENIQTM by Lux) for the treatment of uveitis. Voclosporin
has also entered First-in-Man trials as the drug utilized in the CINATRA(TM)
Drug Coated Coronary Stent system developed by the Company's partner, Atrium
Medical Corporation.
    Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can be found
at www.isotechnika.com or www.SEDAR.com.

    Forward-Looking Statements

    This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

    %SEDAR: 00010508E




For further information:

For further information: Robert Foster, Chairman & CEO, Isotechnika
Inc., Phone: (780) 487-1600 (x247), Fax: (780) 484-4105, E-mail:
rfoster@isotechnika.com; Stephanie Gillis-Paulgaard, Director, Communications,
Isotechnika Inc., Phone: (780) 909-4661, Fax: (780) 484-4105, E-mail:
sgillis-paulgaard@isotechnika.com

Organization Profile

ISOTECHNIKA PHARMA INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890